Advertisement

Picture Berlin Partner Bionnale the Annual Life Sciences Event 650x80px
Document › Details

Celeris Therapeutics GmbH. (11/29/21). "Press Release: Celeris Therapeutics, Inc., Pioneering AI-driven Degrader Discovery, Appoints Nick DeHaan as VP, Head of Partnering". Menlo Park, CA.

Organisation Organisation Celeris Therapeutics Inc.
  Group Celeris Therapeutics (CelerixTx) (Group)
Products Product proximity-inducing compounds (PIC™ degrader drugs)
  Product 2 Celeris One™ platform
Persons Person DeHaan, Nick (Celeris Therapeutics 202111– VP Head of Partnering before Atomwise)
  Person 2 Trummer, Christopher (Celeris Therapeutics 202202 CEO + Co-Founder)
     


Silicon Valley-based startup recruits experienced business development leader to drive growth in AI-based protein degrader discovery partnerships


Nick brings more than seven years of experience in establishing and managing early-stage drug discovery collaborations and programs. His responsibilities include forming commercial partnerships and contributing to business and marketing efforts.

Nick gained experience setting up computationally-enabled drug discovery collaborations and commercial agreements as a Partnering Executive at Atomwise. He also managed a commercialization grant program which included drug discovery and development efforts at the University of Michigan Medical School. He holds an MsE from the University of Michigan in Entrepreneurship, with a focus on bioinformatics.

"Nick is an excellent addition to the team and our foundation in Silicon Valley. He brings experience and a great blend of business and AI-based drug discovery knowledge to create value for our collaboration partners.", said Christopher Trummer, President and CEO of Celeris Therapeutics. "We're glad to gain traction in the US market with Nick as our VP. His network, knowledge, and skills position us perfectly in this market.", adds Jakob Hohenberger, CFO/COO.

"I'm honored to join the CelerisTx team and for the opportunity to help our partners develop degrader drugs for patients with significant unmet medical needs," stated Nick DeHaan, the new VP, Head of Partnerships at Celeris Therapeutics.


About Celeris Therapeutics

Celeris Therapeutics is a tech-enabled early-stage drug discovery company that uses innovative, computer-based methods to develop degrader drugs for currently undruggable pathogenic proteins that are related to Alzheimer's, Parkinson's, various types of cancers, and other diseases.

Celeris Therapeutics' technical solution is the platform Celeris One. Celeris Therapeutics offers collaboration with pharma and biotech companies to jointly work on drugs against unmet medical needs and develops its own in-house drug pipeline.

Celeris Therapeutics has offices in Menlo Park, CA, and Graz, Austria.

To learn more, visit www.celeristx.com


Christopher Trummer
Celeris Therapeutics
+43 660 3837648
email us here
Visit us on social media:
Twitter
LinkedIn

   
Record changed: 2022-03-17

Advertisement

Picture [iito] No Tracking 650x100px

More documents for Celeris Therapeutics (CelerixTx) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Bionnale the Annual Life Sciences Event 650x80px




» top